Laurus Labs · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Net debt of INR 2,368 crore with debt/EBITDA at 3x (vs historical range). Management aims to reduce this to below 2x as EBITDA improves, but the high debt burden constrains financial flexibility and increases vulnerability to any revenue shortfalls.
CDMO revenue has remained essentially flat at ~INR 900 crore over FY2022-FY2024 despite significant CapEx deployment. Management acknowledged this 'transitionary period' but gave no specific timeline for meaningful acceleration beyond Animal Health ramp-up.
Other API segment (cardiovascular, diabetes, asthma) declined 22% in FY2024 due to challenging price environment, with management indicating pricing headwinds may continue into FY2025. This segment represents ~25% of API sales but affects overall margins.
While the company added 2 new CDMO clients and is receiving more RFPs, management explicitly stated 'nothing meaningful will come in the 12 months from the new clients' and that onboarding takes time. Analysts questioned the gap between pipeline activity and revenue conversion.
